From: Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Event, n (%) | Time to first event treatment comparison (tiotropium–placebo) | |||
---|---|---|---|---|
Tiotropium 18 μg | Placebo | HR (95% CI) | Pvalue | |
Overall | 2811 (100.0) | 2841 (100.0) | ||
SGRQ deterioration, trough FEV1 decline ≥100 mL, moderate/severe exacerbation | 2310 (82.2) | 2431 (85.6) | 0.71 (0.67, 0.75) | < 0.0001 |
Moderate/severe exacerbation | 1884 (67.0) | 1930 (67.9) | 0.86 (0.81, 0.92) | < 0.0001 |
Trough FEV1 decline ≥100 mL | 1028 (36.6) | 1475 (51.9) | 0.53 (0.49, 0.58) | < 0.0001 |
SGRQ score increase ≥4 units | 1077 (38.3) | 1262 (44.4) | 0.72 (0.66, 0.78) | < 0.0001 |
GOLD 2 | 1310 (100.0) | 1293 (100.0) | ||
SGRQ deterioration, trough FEV1 decline ≥100 mL, moderate/severe exacerbation | 1053 (80.4) | 1122 (86.8) | 0.70 (0.65, 0.77) | < 0.0001 |
Moderate/severe exacerbation | 780 (59.5) | 835 (64.6) | 0.83 (0.75, 0.92) | 0.0002 |
Trough FEV1 decline ≥100 mL | 564 (43.1) | 780 (60.3) | 0.54 (0.49, 0.61) | < 0.0001 |
SGRQ score increase ≥4 units | 487 (37.2) | 594 (45.9) | 0.71 (0.63, 0.80) | < 0.0001 |
GOLD 3 | 1239 (100.0) | 1266 (100.0) | ||
SGRQ deterioration, trough FEV1 decline ≥100 mL, moderate/severe exacerbation | 1036 (83.6) | 1091 (86.2) | 0.69 (0.63, 0.75) | < 0.0001 |
Moderate/severe exacerbation | 896 (72.3) | 900 (71.1) | 0.86 (0.78, 0.94) | 0.0010 |
Trough FEV1 decline ≥100 mL | 413 (33.3) | 618 (48.8) | 0.51 (0.45, 0.58) | < 0.0001 |
SGRQ score increase ≥4 units | 491 (39.6) | 563 (44.5) | 0.71 (0.63, 0.81) | < 0.0001 |
GOLD 4 | 231 (100.0) | 250 (100.0) | ||
SGRQ deterioration, trough FEV1 decline ≥100 mL, moderate/severe exacerbation | 197 (85.3) | 191 (76.4) | 0.90 (0.74, 1.10) | 0.3079 |
Moderate/severe exacerbation | 186 (80.5) | 171 (68.4) | 1.00 (0.81, 1.23) | 0.9798 |
Trough FEV1 decline ≥100 mL | 41 (17.7) | 59 (23.6) | 0.57 (0.39, 0.86) | 0.0066 |
SGRQ score increase ≥4 units | 90 (39.0) | 88 (35.2) | 0.83 (0.62, 1.11) | 0.2105 |